Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer—The CONKO-008 Phase I Investigation. The gene discussed is ERBB2; the disease is familial pancreatic carcinoma.